FibroBiologics Announces $25 Million Financing
23 déc. 2024 07h55 HE
|
Fibrobiologics, Inc.
HOUSTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly
19 nov. 2024 09h15 HE
|
Fibrobiologics, Inc.
HOUSTON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of...
FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics
14 nov. 2024 09h15 HE
|
Fibrobiologics, Inc.
HOUSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
12 nov. 2024 16h20 HE
|
Fibrobiologics, Inc.
Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the...
FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology
29 oct. 2024 09h15 HE
|
Fibrobiologics, Inc.
HOUSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024
28 oct. 2024 09h31 HE
|
Fibrobiologics, Inc.
HOUSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases
18 oct. 2024 08h30 HE
|
Fibrobiologics, Inc.
HOUSTON, Oct. 18, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) (“FibroBiologics”) and Charles River Laboratories (“Charles River”), a leading global drug discovery, development,...
FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office
16 oct. 2024 09h15 HE
|
Fibrobiologics, Inc.
HOUSTON, Oct. 16, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit
11 oct. 2024 09h31 HE
|
Fibrobiologics, Inc.
HOUSTON, Oct. 11, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
FibroBiologics to Present at 2024 Cell & Gene Meeting on the Mesa
30 sept. 2024 09h31 HE
|
Fibrobiologics, Inc.
HOUSTON, Sept. 30, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...